206 related articles for article (PubMed ID: 37192586)
61. Monitoring of safety and effectiveness of cladribine in multiple sclerosis patients over 50 years.
Disanto G; Moccia M; Sacco R; Spiezia AL; Carotenuto A; Brescia Morra V; Gobbi C; Zecca C
Mult Scler Relat Disord; 2022 Feb; 58():103490. PubMed ID: 35007823
[TBL] [Abstract][Full Text] [Related]
62. Estimating the comparative efficacy of cladribine tablets versus alternative disease modifying treatments in active relapsing-remitting multiple sclerosis: adjusting for patient characteristics using meta-regression and matching-adjusted indirect treatment comparison approaches.
Berardi A; Siddiqui MK; Treharne C; Harty G; Wong SL
Curr Med Res Opin; 2019 Aug; 35(8):1371-1378. PubMed ID: 30786783
[No Abstract] [Full Text] [Related]
63. Long-term management of multiple sclerosis patients treated with cladribine tablets: an expert opinion.
Meuth SG; Bayas A; Kallmann B; Kleinschnitz C; Linker R; Rieckmann P; Mäurer M
Expert Opin Pharmacother; 2020 Nov; 21(16):1965-1969. PubMed ID: 32658554
[TBL] [Abstract][Full Text] [Related]
64. Real-World Retrospective Analysis of Alemtuzumab Outcomes in Relapsing-Remitting Multiple Sclerosis: The LEMCAM Study.
Costa-Frossard França L; Meca Lallana V; Labiano-Fontcuberta A; Blasco R; Monreal E; Martínez Ginés ML; Aguirre C; Sabin Muñoz J; Sainz de la Maza S; Cuello JP; Díaz-Pérez C; Chico García JL; Lozano Ros A; Rodríguez Jorge F; Martínez Martínez S; García Domínguez JM
CNS Drugs; 2024 Mar; 38(3):231-238. PubMed ID: 38418770
[TBL] [Abstract][Full Text] [Related]
65. Assessing the Long-Term Effectiveness of Cladribine vs. Placebo in the Relapsing-Remitting Multiple Sclerosis CLARITY Randomized Controlled Trial and CLARITY Extension Using Treatment Switching Adjustment Methods.
Bell Gorrod H; Latimer NR; Damian D; Hettle R; Harty GT; Wong SL
Adv Ther; 2020 Jan; 37(1):225-239. PubMed ID: 31701485
[TBL] [Abstract][Full Text] [Related]
66. Magnetic Resonance Imaging Evidence Supporting the Efficacy of Cladribine Tablets in the Treatment of Relapsing-Remitting Multiple Sclerosis.
Cortese R; Testa G; Assogna F; De Stefano N
CNS Drugs; 2024 Apr; 38(4):267-279. PubMed ID: 38489020
[TBL] [Abstract][Full Text] [Related]
67. Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis.
Giovannoni G; Cook S; Rammohan K; Rieckmann P; Sørensen PS; Vermersch P; Hamlett A; Viglietta V; Greenberg S;
Lancet Neurol; 2011 Apr; 10(4):329-37. PubMed ID: 21397565
[TBL] [Abstract][Full Text] [Related]
68. Analysis of frequency and severity of relapses in multiple sclerosis patients treated with cladribine tablets or placebo: The CLARITY and CLARITY Extension studies.
De Stefano N; Sormani MP; Giovannoni G; Rammohan K; Leist T; Coyle PK; Dangond F; Keller B; Alexandri N; Galazka A
Mult Scler; 2022 Jan; 28(1):111-120. PubMed ID: 33969750
[TBL] [Abstract][Full Text] [Related]
69. Cost Effectiveness of Cladribine Tablets for the Treatment of Relapsing-Remitting Multiple Sclerosis in The Netherlands.
Michels RE; de Fransesco M; Mahajan K; Hengstman GJD; Schiffers KMH; Budhia S; Harty G; Krol M
Appl Health Econ Health Policy; 2019 Dec; 17(6):857-873. PubMed ID: 31444659
[TBL] [Abstract][Full Text] [Related]
70. Clinical predictors of Dimethyl Fumarate response in multiple sclerosis: a real life multicentre study.
Lanzillo R; Moccia M; Palladino R; Signoriello E; Carotenuto A; Maniscalco GT; Saccà F; Bonavita S; Russo CV; Iodice R; Petruzzo M; Sinisi L; De Angelis M; Lavorgna L; De Rosa A; Romano F; Orlando V; Ronga B; Florio C; Lus G; Brescia Morra V
Mult Scler Relat Disord; 2020 Feb; 38():101871. PubMed ID: 31786463
[TBL] [Abstract][Full Text] [Related]
71. Effectiveness, safety and health-related quality of life of multiple sclerosis patients treated with fingolimod: results from a 12-month, real-world, observational PERFORMS study in the Middle East.
Achiron A; Aref H; Inshasi J; Harb M; Alroughani R; Bijarnia M; Cooke K; Yuksel O
BMC Neurol; 2017 Aug; 17(1):150. PubMed ID: 28784108
[TBL] [Abstract][Full Text] [Related]
72. [Cladribine tablets : Oral immunotherapy of relapsing-remitting multiple sclerosis with short yearly treatment periods].
Meuth SG; Ruck T; Aktas O; Hartung HP
Nervenarzt; 2018 Aug; 89(8):895-907. PubMed ID: 29523912
[TBL] [Abstract][Full Text] [Related]
73. Autoimmune glomerulonephritis in a multiple sclerosis patient after cladribine treatment.
Schönfelder K; Schuh H; Pfister F; Krämer J; Eisenberger U; Skuljec J; Hackert J; Ruck T; Pfeuffer S; Fleischer M; Gäckler A; Hagenacker T; Kribben A; Meuth SG; Kleinschnitz C; Pul R
Mult Scler; 2021 Oct; 27(12):1960-1964. PubMed ID: 34165361
[TBL] [Abstract][Full Text] [Related]
74. Benefit-risk Assessment of Cladribine Using Multi-criteria Decision Analysis (MCDA) for Patients With Relapsing-remitting Multiple Sclerosis.
Vermersch P; Martinelli V; Pfleger C; Rieckmann P; Alonso-Magdalena L; Galazka A; Dangond F; Phillips L
Clin Ther; 2019 Feb; 41(2):249-260.e18. PubMed ID: 30846120
[TBL] [Abstract][Full Text] [Related]
75. Relapses in people with multiple sclerosis treated with cladribine tablets followed for up to 5 years: a plain language summary.
Stefano N; Sormani MP; Giovannoni G; Rammohan K; Leist TP; Coyle PK; Dangond F; Alexandri N; Galazka A
Neurodegener Dis Manag; 2022 Dec; 12(6):303-310. PubMed ID: 36017797
[TBL] [Abstract][Full Text] [Related]
76. CSF levels of Chitinase3like1 correlate with early response to cladribine in multiple sclerosis.
Marastoni D; Foschi M; Eccher C; Crescenzo F; Mazziotti V; Tamanti A; Bajrami A; Camera V; Ziccardi S; Guandalini M; Bosello F; Anni D; Virla F; Turano E; Romoli M; Mariotti R; Pizzini FB; Bonetti B; Calabrese M
Front Immunol; 2024; 15():1343892. PubMed ID: 38404586
[TBL] [Abstract][Full Text] [Related]
77. Prospective observational study to evaluate treatment satisfaction and effectiveness in patients with relapsing multiple sclerosis starting cladribine tablets (CLADREAL) in Italy.
Filippi M; Ferrè L; Zanetta C; Rizzi C; Pessina G; Assogna F; Rocca MA
Front Neurol; 2024; 15():1379712. PubMed ID: 38638312
[TBL] [Abstract][Full Text] [Related]
78. [Pharmacoeconomic aspects of using cladribine (in tablets) for treatment of adult patients with remitting multiple sclerosis].
Avxentyev NA; Davydovskaya MV; Makarova YV; Frolov MY; Klabukova DL
Zh Nevrol Psikhiatr Im S S Korsakova; 2021; 121(8):30-36. PubMed ID: 34481433
[TBL] [Abstract][Full Text] [Related]
79. Safety and efficacy of cladribine in multiple sclerosis: a systematic review and meta-analysis.
Nabizadeh F; Mohamadi M; Rahmani S; Rajabi R; Afrashteh F; Najdaghi S; Mirmosayyeb O
Neurol Sci; 2023 Sep; 44(9):3045-3057. PubMed ID: 37062787
[TBL] [Abstract][Full Text] [Related]
80. A plain language summary on the effectiveness of cladribine tablets compared with other oral treatments for multiple sclerosis: results from the MSBase registry.
Spelman T; Ozakbas S; Alroughani R; Terzi M; Hodgkinson S; Laureys G; Kalincik T; Der Walt AV; Yamout B; Lechner-Scott J; Soysal A; Kuhle J; Sanchez-Menoyo JL; Morgado YB; Spitaleri D; Pesch VV; Horakova D; Ampapa R; Patti F; Macdonell R; Al-Asmi A; Gerlach O; Oh J; Altintas A; Tundia N; Wong SL; Butzkueven H;
Neurodegener Dis Manag; 2023 Aug; 13(4):215-221. PubMed ID: 37287269
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
